Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Therapeutics suspends lung cancer trial
The Data Safety Monitoring Board (DSMB) has recommended that Cell Therapeutics suspends enrollment on the trial to assess differences in deaths observed between patients treated with Xyotax and
The Data Safety Monitoring Board (DSMB) has recommended that Cell Therapeutics suspends enrollment on the trial to assess differences in deaths observed between patients treated with Xyotax and
AstraZeneca has completed consultations with regulators in the US and EU about the drug. In order to meet the regulatory needs of both agencies, AstraZeneca must implement a
The agreement will focus on drugs that are linked to apoE-regulated mechanisms in the body, which were discovered by the Gladstone Institutes. The deal provides Merck with an
NitroMist is NovaDel’s first product approval utilizing its proprietary oral spray technology. The North American commercial rights for NitroMist have been licensed to Par Pharmaceutical. “With this approval,
Leo Pharma was granted exclusive worldwide rights to develop, manufacture, and commercialize this novel preclinical HDAC inhibitor for the treatment of psoriasis and other dermatological disorders. Under the
The compound is an oral prodrug of the company’s lead compound, tezampanel. This phase I study was designed to evaluate the safety, tolerability and pharmacokinetics of NGX426, as
The FDA previously approved an investigational new drug application for recombinant human Mannose-Binding Lectin (rhMBL) for the prevention and treatment of severe infections in patients with multiple myeloma.
Gamida Cell is developing StemEx in a joint venture with Teva Pharmaceutical Industries. The design of the study was submitted under a special protocol assessment. “The design and
The only drugs currently available for Alzheimer’s patients are those that alleviate symptoms. Research has shown that a compound called tramiprosate has reduced levels of a marker for
Importantly, the results were comparable for ZIO-201 administered as a single dose, a schedule currently being explored in phase I clinical study, or as three consecutive daily doses,